JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157
JP Morgan analyst Anupam Rama initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rating and announces Price Target of $157.
Stocks · News reference
Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Celcuity Inc. (CELC)
Filed: 2026-08-26 AccNo: 0001193125-26-365975 Size: 406 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175
Guggenheim analyst Brad Canino maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $165 to $175.